Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
Novel agents such as lenalidomide have demonstrated responses similar to high-dose melphalan and autologous stem cell transplant in multiple myeloma. For patients who are started on lenalidomide, it is advisable to collect stem cells early if future transplant is contemplated. We are reporting a pat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2012-12-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/4509 |
id |
doaj-4991d1f571e14284be3168549dd2ec58 |
---|---|
record_format |
Article |
spelling |
doaj-4991d1f571e14284be3168549dd2ec582020-11-25T03:39:59ZengPAGEPress PublicationsHematology Reports2038-83222038-83302012-12-0144e26e2610.4081/hr.2012.e262355Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myelomaRishi Agarwal0Muneer H. Abidi1UT Houston MD Anderson Cancer Center, Houston, TXKarmanos Cancer Institute, Detroit, MI; Wayne State University, Detroit, MINovel agents such as lenalidomide have demonstrated responses similar to high-dose melphalan and autologous stem cell transplant in multiple myeloma. For patients who are started on lenalidomide, it is advisable to collect stem cells early if future transplant is contemplated. We are reporting a patient who underwent successful stem cell mobilization after 68 cycles of lenalidomide. A 60-year old male presented with back pain. He was diagnosed with stage IIA, IgA multiple myeloma. He was enrolled in a clinical trial and was randomized to receive lenalidomide plus dexamethasone. He received a total of 68 cycles of lenalidomide before progressing. He underwent mobilization of stem cells using filgrastim and plerixafor. He underwent successful stem cell transplant. Longer duration of lenalidomide adversely effects stem cell mobilization. To the best of our knowledge, there has been no other case reported in which stem cell mobilization was feasible after such a long (68 months) duration of uninterrupted lenalidomide therapy.http://www.pagepress.org/journals/index.php/hr/article/view/4509ASCT, lenalidomide, filgrastim, plerixafor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rishi Agarwal Muneer H. Abidi |
spellingShingle |
Rishi Agarwal Muneer H. Abidi Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma Hematology Reports ASCT, lenalidomide, filgrastim, plerixafor |
author_facet |
Rishi Agarwal Muneer H. Abidi |
author_sort |
Rishi Agarwal |
title |
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
title_short |
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
title_full |
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
title_fullStr |
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
title_full_unstemmed |
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
title_sort |
successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma |
publisher |
PAGEPress Publications |
series |
Hematology Reports |
issn |
2038-8322 2038-8330 |
publishDate |
2012-12-01 |
description |
Novel agents such as lenalidomide have demonstrated responses similar to high-dose melphalan and autologous stem cell transplant in multiple myeloma. For patients who are started on lenalidomide, it is advisable to collect stem cells early if future transplant is contemplated. We are reporting a patient who underwent successful stem cell mobilization after 68 cycles of lenalidomide. A 60-year old male presented with back pain. He was diagnosed with stage IIA, IgA multiple myeloma. He was enrolled in a clinical trial and was randomized to receive lenalidomide plus dexamethasone. He received a total of 68 cycles of lenalidomide before progressing. He underwent mobilization of stem cells using filgrastim and plerixafor. He underwent successful stem cell transplant. Longer duration of lenalidomide adversely effects stem cell mobilization. To the best of our knowledge, there has been no other case reported in which stem cell mobilization was feasible after such a long (68 months) duration of uninterrupted lenalidomide therapy. |
topic |
ASCT, lenalidomide, filgrastim, plerixafor |
url |
http://www.pagepress.org/journals/index.php/hr/article/view/4509 |
work_keys_str_mv |
AT rishiagarwal successfulautologousstemcellcollectionwithfilgrastimandplerixaforafterlongtermlenalidomidetherapyformultiplemyeloma AT muneerhabidi successfulautologousstemcellcollectionwithfilgrastimandplerixaforafterlongtermlenalidomidetherapyformultiplemyeloma |
_version_ |
1724537224398110720 |